#Denmark #Copenhagen #Antag Therapeutics #AT-7687 #Joerg Moeller

Antag Therapeutics Appoints Dr. Joerg Moeller as New CEO

On January 8, 2025, Antag Therapeutics, a leading biopharmaceutical company focused on groundbreaking treatments for obesity, announced the appointment of Dr. Joerg Moeller as its new Chief Executive Officer. This pivotal leadership change comes as the company prepares for an important phase in its clinical development journey with its first-in-class lead candidate, AT-7687. Dr. Moeller succeeds Dr. Alexander Sparre-Ulrich, who played a crucial role in establishing the company as a frontrunner in GIP receptor antagonism, a novel approach in addressing obesity.

Dr. Moeller brings over 30 years of industry experience which includes leadership roles in multinational organizations, showcasing a proven track record in driving strategic growth and innovation. Prior to joining Antag, he was Head of Global Research and Development at Bayer AG’s Pharmaceutical Division. His tenure at Bayer was marked by successful launches of multiple innovative therapies across diverse therapeutic areas such as oncology, cardiovascular, and infectious diseases, building a rich portfolio that aligns well with the ambitious goals of Antag Therapeutics.

Philip Just Larsen, MD, PhD, the Chair of Antag Therapeutics’ Board of Directors, expressed confidence in Dr. Moeller's capabilities, emphasizing his background in pharmaceutical innovation and his ability to lead the company into its next growth phase. Dr. Larsen thanked Dr. Sparre-Ulrich for his instrumental contributions and stated that the groundwork he laid would continue to support Antag’s mission of providing transformative therapies for obesity and metabolic disorders.

The year 2024 proved to be a landmark year for Antag Therapeutics, highlighted by the successful completion of an €80 million Series A financing and securing FDA IND clearance for AT-7687. This drug is a novel, once-weekly subcutaneous antagonist that targets the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR). By enhancing GLP-1-based therapies while addressing tolerability issues, AT-7687 is anticipated to set a new standard in obesity treatment, promising significant weight loss and metabolic benefits for patients.

In his first statement as CEO, Dr. Moeller expressed enthusiasm about Antag's innovative approach and its potential to fundamentally change the obesity treatment landscape. He highlighted the importance of tackling the global obesity epidemic and improving patient care through advanced therapeutic solutions.

With plans to focus on advancing its injectable therapies pipeline, Dr. Moeller is committed to working closely with Dr. Sparre-Ulrich and the talented leadership team at Antag. His goal is to not only enhance the company's research objectives but also to fortify its position as a pioneer in GIP receptor antagonism.

In the upcoming weeks, Antag’s management will be attending the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025, where they aim to foster partnerships that will aid in the further development of innovative therapies against obesity.

About Antag Therapeutics

Antag Therapeutics focuses on discovering and developing novel treatments for obesity and related cardiometabolic diseases. The company leverages the potential of GIP receptor antagonists to improve patient outcomes through innovative scientific solutions. For more information, visit Antag Therapeutics.

About AT-7687

AT-7687 stems from pioneering research initiated by Professor Jens Holst, known for discovering GLP-1. The drug has shown promising preclinical data and benefits from robust genetic validation, supporting its potential in reducing GIP receptor activity and associated fat accumulation.